Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.20
IGC's Cash to Debt is ranked lower than
88% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. IGC: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
IGC' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.36 Max: N/A
Current: 0.2
Equity to Asset 0.71
IGC's Equity to Asset is ranked higher than
60% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IGC: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
IGC' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.68 Max: 0.77
Current: 0.71
0.35
0.77
F-Score: 5
Z-Score: -2.89
M-Score: -3.27
WACC vs ROIC
13.08%
-18.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -42.28
IGC's Operating margin (%) is ranked lower than
85% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. IGC: -42.28 )
Ranked among companies with meaningful Operating margin (%) only.
IGC' s Operating margin (%) Range Over the Past 10 Years
Min: -194.13  Med: -30.93 Max: 64.93
Current: -42.28
-194.13
64.93
Net-margin (%) -45.87
IGC's Net-margin (%) is ranked lower than
86% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. IGC: -45.87 )
Ranked among companies with meaningful Net-margin (%) only.
IGC' s Net-margin (%) Range Over the Past 10 Years
Min: -496.83  Med: -60.08 Max: 43.6
Current: -45.87
-496.83
43.6
ROE (%) -23.57
IGC's ROE (%) is ranked lower than
80% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. IGC: -23.57 )
Ranked among companies with meaningful ROE (%) only.
IGC' s ROE (%) Range Over the Past 10 Years
Min: -128.75  Med: -17.59 Max: 2.94
Current: -23.57
-128.75
2.94
ROA (%) -16.74
IGC's ROA (%) is ranked lower than
80% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. IGC: -16.74 )
Ranked among companies with meaningful ROA (%) only.
IGC' s ROA (%) Range Over the Past 10 Years
Min: -75.62  Med: -10.55 Max: 2.22
Current: -16.74
-75.62
2.22
ROC (Joel Greenblatt) (%) -30.72
IGC's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. IGC: -30.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IGC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -224.09  Med: -32.31 Max: 853.42
Current: -30.72
-224.09
853.42
Revenue Growth (3Y)(%) -28.90
IGC's Revenue Growth (3Y)(%) is ranked lower than
92% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IGC: -28.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IGC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -53.20 Max: 275.6
Current: -28.9
0
275.6
EBITDA Growth (3Y)(%) -50.20
IGC's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IGC: -50.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IGC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -70.6  Med: -57.55 Max: 115.9
Current: -50.2
-70.6
115.9
EPS Growth (3Y)(%) -51.00
IGC's EPS Growth (3Y)(%) is ranked lower than
96% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. IGC: -51.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IGC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.7  Med: -51.00 Max: 72.7
Current: -51
-69.7
72.7
» IGC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IGC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XPAE:PHARMACARE, ASX:MXC, ROCO:6467, NAS:ACUR, ROCO:4127, NAS:PTX » details
Traded in other countries:IGS1.Germany,
India Globalization Capital Inc is engaged in developing & commercializing a portfolio of proprietary cannabinoid based biopharmaceutical therapies for end of life supportive care, hospice care, & chronic neurological & oncological diagnosis.

India Globalization Capital, Inc. is a Maryland corporation, organized on April 29, 2005. It is a materials and construction company offering services including: civil construction of roads and highways, the construction and maintenance of high temperature cement and steel plants, operations and supply of rock aggregate and the export of iron ore to China. The Company's present and past clients include various Indian government organizations and steel mills in China. Including its subsidiaries, it has approximately 200 employees and contractors. It is focused on winning construction contracts, building out rock aggregate quarries and setting up relations and export hubs for the export of iron ore to China. India has strict environmental, occupational, health and safety regulations.

Ratios

vs
industry
vs
history
P/B 0.64
IGC's P/B is ranked higher than
95% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. IGC: 0.64 )
Ranked among companies with meaningful P/B only.
IGC' s P/B Range Over the Past 10 Years
Min: 0.19  Med: 0.60 Max: 2.15
Current: 0.64
0.19
2.15
P/S 1.02
IGC's P/S is ranked higher than
85% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. IGC: 1.02 )
Ranked among companies with meaningful P/S only.
IGC' s P/S Range Over the Past 10 Years
Min: 0.11  Med: 1.01 Max: 7.46
Current: 1.02
0.11
7.46
Current Ratio 2.69
IGC's Current Ratio is ranked higher than
56% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. IGC: 2.69 )
Ranked among companies with meaningful Current Ratio only.
IGC' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.89 Max: 22.08
Current: 2.69
0.97
22.08
Quick Ratio 2.18
IGC's Quick Ratio is ranked higher than
57% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. IGC: 2.18 )
Ranked among companies with meaningful Quick Ratio only.
IGC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.76 Max: 22.08
Current: 2.18
0.95
22.08
Days Inventory 42.21
IGC's Days Inventory is ranked higher than
86% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. IGC: 42.21 )
Ranked among companies with meaningful Days Inventory only.
IGC' s Days Inventory Range Over the Past 10 Years
Min: 13.8  Med: 25.63 Max: 158.65
Current: 42.21
13.8
158.65
Days Sales Outstanding 38.33
IGC's Days Sales Outstanding is ranked higher than
82% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. IGC: 38.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.19  Med: 96.84 Max: 2321.79
Current: 38.33
47.19
2321.79
Days Payable 9.52
IGC's Days Payable is ranked lower than
96% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. IGC: 9.52 )
Ranked among companies with meaningful Days Payable only.
IGC' s Days Payable Range Over the Past 10 Years
Min: 6.2  Med: 29.71 Max: 362.54
Current: 9.52
6.2
362.54

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.71
IGC's Price/Tangible Book is ranked higher than
94% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. IGC: 0.71 )
Ranked among companies with meaningful Price/Tangible Book only.
IGC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.25  Med: 1.19 Max: 5.23
Current: 0.71
0.25
5.23
Price/Projected FCF 1.48
IGC's Price/Projected FCF is ranked higher than
77% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. IGC: 1.48 )
Ranked among companies with meaningful Price/Projected FCF only.
IGC' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.5  Med: 1.18 Max: 2.41
Current: 1.48
0.5
2.41
Price/Median PS Value 1.00
IGC's Price/Median PS Value is ranked higher than
75% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. IGC: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
IGC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.16 Max: 5.92
Current: 1
0.13
5.92
Earnings Yield (Greenblatt) (%) -26.60
IGC's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. IGC: -26.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IGC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -26.6  Med: 6.75 Max: 15.1
Current: -26.6
-26.6
15.1

More Statistics

Revenue (TTM) (Mil) $7.26
EPS (TTM) $ -0.18
Beta1.65
Short Percentage of Float0.05%
52-Week Range $0.14 - 0.83
Shares Outstanding (Mil)17.97
» More Articles for IGC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 20 2016
EXEL INDUSTRIES :First Bond Issue on the Euro PP market for the EXEL Industries Group May 18 2016
EXEL INDUSTRIES: 2015-2016 first-half results Increased income and Strategic Acquisition in the USA Apr 21 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities,... Apr 06 2016
IGC Invests in Farming Facility Accelerating Initiative for the Legal Cannabis Farming Marketplace Apr 06 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities,... Mar 30 2016
India Globalization Capital Raises $300 Thousand in Direct Equity Investment Mar 29 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities,... Mar 18 2016
India Globalization Capital Raises $600 Thousand in Direct Equity Investment Mar 17 2016
IGC Files International Applications for Cannabinoid Composition and Method Patents Mar 15 2016
Top Small Cap Stocks to Watch, Monday 3/14/2016 Mar 14 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Other Events, Financial Statements and... Mar 09 2016
IGC Completes Satisfactory Settlement with Sricon Mar 08 2016
INDIA GLOBALIZATION CAPITAL, INC. Financials Mar 01 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities,... Mar 01 2016
INDIA GLOBALIZATION CAPITAL, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 29 2016
India Globalization Capital $50 Strike Warrants to be Removed from NYSE MKT Feb 29 2016
India Globalization Capital, Inc. Earnings Analysis: Q3, 2016 By the Numbers Feb 25 2016
India Globalization Capital Raises $600 Thousand in Direct Equity Investment Feb 25 2016
IGC Announces Third Quarter Financial Results Feb 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)